

## Landscape of candidate vaccines in clinical development

Friday, March 12, 2021

**DISCLAIMER:** These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week is highlighted in yellow

(NCT04510207 \*) This Phase 3 trial assesses both the Wuhan and Beijing vaccine in the same study.

\*\*Pending confirmation on the phase of study which is not specified in the registry.

Information highlighted in red indicates a change in the development of the vaccine

ID	Vaccine platform acronym	Vaccine platform description	Type of candidate vaccine	Number of doses	Schedule	Route of administration	Developers	Phase	Current status of clinical development	
									Phase 1	Phase 1/2
1	IV	Inactivated virus	CoronaVac; SARS-CoV-2 vaccine (inactivated)	2	Day 0 + 14	IM	Sinovac Research and Development Co., Ltd	Phase 4		<a href="#">NCT04383574</a> <a href="#">Study Report</a> <a href="#">NCT04352608</a> <a href="#">NCT04551547</a> <a href="#">Study Report</a> <a href="#">Study Report</a>
2	IV	Inactivated virus	Inactivated SARS-CoV-2 vaccine (Vero cell)	2	Day 0 + 21	IM	Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products	Phase 3		<a href="#">ChiCTR2000031809</a>  <a href="#">Interim Report</a>
3	IV	Inactivated virus	Inactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP-CorV	2	Day 0 + 21	IM	Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products	Phase 3		<a href="#">ChiCTR2000032459</a>  <a href="#">Study Report</a>
4	VVnr	Viral vector (Non-replicating)	ChAdOx1-S - (AZD1222) (Covishield)	1-2	Day 0 + 28	IM	AstraZeneca + University of Oxford	Phase 4	<a href="#">PACTR202005681895696</a>	<a href="#">PACTR202006922165132</a> <a href="#">2020-001072-15</a> <a href="#">Interim Report</a> <a href="#">NCT04568031</a> <a href="#">Study Report</a> <a href="#">NCT04444674</a> <a href="#">NCT04324606</a> <a href="#">Study Report</a> <a href="#">Study Report</a> <a href="#">Study Report</a> <a href="#">NCT04684446</a> <a href="#">ISRCTN15638344</a> <a href="#">NCT04760730</a>
5	VVnr	Viral vector (Non-replicating)	Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)	1	Day 0	IM	CanSino Biological Inc./Beijing Institute of Biotechnology	Phase 3	<a href="#">ChiCTR2000030906</a>  <a href="#">NCT04313127</a> <a href="#">NCT04568811</a> <a href="#">NCT04552366</a> <a href="#">Study Report</a>	<a href="#">NCT04398147</a>
6	VVnr	Viral vector (Non-replicating)	Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S)	2	Day 0 + 21	IM	Gamaleya Research Institute ; Health Ministry of the Russian Federation	Phase 3		<a href="#">NCT04436471</a>  <a href="#">NCT04437875</a> <a href="#">NCT04713488</a> <a href="#">Study Report</a> <a href="#">NCT04760730</a>
7	VVnr	Viral vector (Non-replicating)	Ad26.COV2.S	1-2	Day 0 or Day 0 +56	IM	Janssen Pharmaceutical	Phase 3	<a href="#">NCT04509947</a>	<a href="#">NCT04436276</a>  <a href="#">Study Report</a> <a href="#">Study Report</a>
8	PS	Protein subunit	SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M)	2	Day 0 + 21	IM	Novavax	Phase 3		<a href="#">NCT04368988</a>  <a href="#">Study Report</a> <a href="#">Study Report</a>

9	RNA	RNA based vaccine	mRNA -1273	2	Day 0 + 28	IM	Moderna + National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	<a href="#">NCT04283461</a> <a href="#">Interim Report</a> <a href="#">Study Report</a>	<a href="#">NCT04677660</a> <a href="#">NCT04712110</a>
10	RNA	RNA based vaccine	BNT162 (3 LNP-mRNAs ), also known as "Comirnaty"	2	Day 0 + 21	IM	Pfizer/BioNTech + Fosun Pharma	Phase 4	<a href="#">NCT04523571</a> <a href="#">Study Report</a> <a href="#">ChiCTR2000034825</a>	<a href="#">2020-001038-36</a> <a href="#">NCT04588480</a> <a href="#">NCT04380701</a> <a href="#">Study Report</a> <a href="#">NCT04537949</a> <a href="#">EUCTR2020-003267-26-DE</a> <a href="#">Study Report</a>
11	PS	Protein subunit	Recombinant SARS-CoV-2 vaccine (CHO Cell)	2-3	Day 0 + 28 or Day 0 + 28 + 56	IM	Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences	Phase 3	<a href="#">NCT04445194</a> <a href="#">ChiCTR2000035691</a> <a href="#">NCT04636333</a>	<a href="#">NCT04550351</a>
12	RNA	RNA based vaccine	CVnCoV Vaccine	2	Day 0 + 28	IM	CureVac AG	Phase 3	<a href="#">NCT04449276</a>	
13	IV	Inactivated virus	SARS-CoV-2 vaccine (vero cells)	2	Day 0 + 28	IM	Institute of Medical Biology + Chinese Academy of Medical Sciences	Phase 3		<a href="#">NCT04470609</a>  <a href="#">NCT04412538</a> <a href="#">Study Report</a>
14	IV	Inactivated virus	QazCovid-in® - COVID-19 inactivated vaccine	2	Day 0 + 21	IM	Research Institute for Biological Safety Problems, Rep of Kazakhstan	Phase 3		<a href="#">NCT04530357</a>
15	DNA	DNA based vaccine	INO-4800+electroporation	2	Day 0 + 28	ID	Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd	Phase 2/3	<a href="#">NCT04336410</a> <a href="#">Study Report</a> <a href="#">ChiCTR2000038152</a>	<a href="#">NCT04447781</a>
16	DNA	DNA based vaccine	AG0301-COVID19	2	Day 0 + 14	IM	AnGes + Takara Bio + Osaka University	Phase 2/3		<a href="#">NCT04463472</a> <a href="#">NCT04527081</a> <a href="#">jRCT2051200085</a>
17	DNA	DNA based vaccine	nCov vaccine	3	Day 0 + 28 + 56	ID	Zyodus Cadila	Phase 3		<a href="#">CTRI/2020/07/026352</a>
18	DNA	DNA based vaccine	GX-19	2	Day 0 + 28	IM	Genexine Consortium	Phase 1/2		<a href="#">NCT04445389</a> <a href="#">NCT04715997</a>
19	IV	Inactivated virus	Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152)	2	Day 0 + 14	IM	Bharat Biotech International Limited	Phase 3		<a href="#">NCT04471519</a> <a href="#">Interim Study Report</a> <a href="#">Study Report</a> <a href="#">Study Report</a> <a href="#">CTRI/2020/07/026300</a> <a href="#">CTRI/2020/09/027674</a>
20	PS	Protein subunit	KBP-COVID-19 (RBD-based)	2	Day 0 + 21	IM	Kentucky Bioprocessing Inc.	Phase 1/2		<a href="#">NCT04473690</a>
21	PS	Protein subunit	VAT00002: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production)	2	Day 0 + 21	IM	Sanofi Pasteur + GSK	Phase 3		<a href="#">NCT04537208</a>
22	RNA	RNA based vaccine	ARCT-021	ND	ND	IM	Arcturus Therapeutics	Phase 2		<a href="#">NCT04480957</a>
23	VLP	Virus like particle	RBD SARS-CoV-2 HBsAg VLP vaccine	2	Day 0 + 28	IM	Serum Institute of India + Accelagen Pty + SpyBiotech	Phase 1/2		<a href="#">ACTRN12620000817943</a> <a href="#">ACTRN12620001308987</a>
24	IV	Inactivated virus	Inactivated SARS-CoV-2 vaccine (Vero cell)	1,2 or 3	ND	IM	Beijing Minhai Biotechnology Co	Phase 2	<a href="#">NCT04759273</a>	
25	VVnr	Viral vector (Non-replicating)	GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S)	1	Day 0	IM	ReiThera + Leukocare + Univercells	Phase 2/3	<a href="#">NCT04528641</a>	
26	VVnr	Viral vector (Non-replicating)	VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform	2	Day 0 + 28	Oral	Vaxart	Phase 1	<a href="#">NCT04563702</a>	
27	VVnr	Viral vector (Non-replicating)	MVA-SARS-2-S	2	Day 0 + 28	IM	University of Munich (Ludwig-Maximilians)	Phase 1	<a href="#">NCT04569383</a>	
28	PS	Protein subunit	SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine)	2	Day 0 + 21	IM	Clover Biopharmaceuticals Inc./GSK/Dynavax	Phase 2/3	<a href="#">NCT04405908</a>  <a href="#">Study Report</a> <a href="#">Report</a>	
29	PS	Protein subunit	COVAX-19® Recombinant spike protein + adjuvant	1	Day 0	IM	Vaxine Pty Ltd.	Phase 1	<a href="#">NCT04538852</a>	
		Protein subunit	MF59 adjuvanted SARS-CoV-2 Sclamp vaccine	2	Day 0 + 28	IM	CSL Ltd. + Seqirus + University of Queensland	Phase 1		<i>Development has been suspended and the</i>
30	PS	Protein subunit	MVC-COV1901 (S-2P protein + CpG 1018)	2	Day 0 + 28	IM	Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	<a href="#">NCT04487210</a>	
31	PS	Protein subunit	FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant)	2	Day 0 + 28	IM	Instituto Finlay de Vacunas	Phase 1/2	<a href="#">RPCEC00000338</a>	<a href="#">RPCEC00000332</a>
32	PS	Protein subunit	FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant)	2	Day 0 + 28	IM	Instituto Finlay de Vacunas	Phase 3	<a href="#">RPCEC00000340</a>	
33	PS	Protein subunit	EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)	2	Day 0 + 21	IM	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"	Phase 3		<a href="#">NCT04527575</a>
34	PS	Protein subunit	RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell)	2	Day 0 + 28	IM	West China Hospital + Sichuan University	Phase 2	<a href="#">ChiCTR2000037518</a>	

												<a href="#">NCT04530656</a>	
35	PS	Protein subunit	IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides)	1	Day 0	SC	University Hospital Tuebingen	Phase 1	<a href="#">NCT04546841</a>				
36	PS	Protein subunit	UB-612 (Multi-epitope peptide based S1-RBD-protein based vaccine)	2	Day 0 + 28	IM	COVAXX + United Biomedical Inc	Phase 2/3	<a href="#">NCT04545749</a>				
		Viral vector (Replicating)	V591-001 - Measles-vector based (TMV-o38)	1-2	Day 0 + 28	IM	Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Pittsburgh	Phase 1/2	<a href="#">NCT04497298</a>		<a href="#">CTD4498247</a>		
									<a href="#">NCT04569786</a>				
37	VVr	Viral vector (Replicating)	DeINS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD )	1	Day 0	IN	University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy	Phase 2	<a href="#">ChiCTR2000037782</a>				
38	RNA	RNA based vaccine	LNP-nCoVsaRNA	2	ND	IM	Imperial College London	Phase 1	<a href="#">ISRCTN17072692</a>				
39	RNA	RNA based vaccine	SARS-CoV-2 mRNA vaccine (ARCoV)	2	Day 0 + 14 or Day 0 + 28	IM	Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences	Phase 1	<a href="#">ChiCTR2000034112</a>				
									<a href="#">ChiCTR2000039212</a>				
40	VLP	Virus like particle	Coronavirus-Like Particle COVID-19 (CoVLP)	2	Day 0 + 21	IM	Medicago Inc.	Phase 2/3	<a href="#">Study Report</a>				
41	VVr + APC	Viral vector (Replicating) + APC	Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs).	3	Day 0 + 14 + 28	SC	Shenzhen Geno-Immune Medical Institute	Phase 1	<a href="#">NCT04299724</a>				
42	VVnr + APC	Viral vector (Non-replicating) + APC	LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens.	1	Day 0	SC & IV	Shenzhen Geno-Immune Medical Institute	Phase 1/2			<a href="#">NCT04276896</a>		
43	PS	Protein subunit	AdimrSC-2f (recombinant RBD +/- Aluminium)	ND	ND	ND	Adimmune Corporation	Phase 1	<a href="#">NCT04522089</a>				
44	DNA	DNA based vaccine	Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation	2	Day 0 + 14	IM	Entos Pharmaceuticals Inc.	Phase 1	<a href="#">NCT04591184</a>				
45	DNA	DNA based vaccine	CORVax - Spike (S) Protein Plasmid DNA Vaccine	2	Day 0 + 14	ID	Providence Health & Services	Phase 1	<a href="#">NCT04627675</a>				
46	RNA	RNA based vaccine	ChulaCoV19 mRNA vaccine	2	Day 0 + 21	IM	Chulalongkorn University	Phase 1	<a href="#">NCT04566276</a>				
47	DNA	DNA based vaccine	bacTRL-Spike oral DNA vaccine	1	Day 0	Oral	Symvivo Corporation	Phase 1	<a href="#">NCT04334980</a>				
48	VVnr	Viral vector (Non-replicating)	Human Adenovirus Type 5: hAd5 S+N vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno.	1-2	Day 0 + 21	SC or Oral	ImmunityBio, Inc. & NantKwest, Inc.	Phase 1	<a href="#">NCT04591717</a> <a href="#">NCT04710303</a> <a href="#">NCT04732468</a>				
49	VVnr	Viral vector (Non-replicating)	COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2	1-2	Day 0 + 28	IM	City of Hope Medical Center + National Cancer Institute	Phase 1	<a href="#">NCT04639466</a> <a href="#">Pre-clinical result</a>				
50	VVr	Viral vector (Replicating)	rVSV-SARS-CoV-2-S Vaccine	1	Day 0	IM	Israel Institute for Biological Research	Phase 1/2			<a href="#">NCT04608305</a>		
51	VVr + APC	Viral vector (Replicating) + APC	Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF	1	Day 0	IM	Alivita Biomedical, Inc. National Institute of Health Research and Development, Ministry of Health Republic of Indonesia	Phase 1/2	<a href="#">NCT04690387</a> <a href="#">NCT04685603</a>		<a href="#">NCT04386252</a>		
52	LAV	Live attenuated virus	COVI-VAC	1-2	Day 0 or Day 0 + 28	IN	Codagenix/Serum Institute of India	Phase 1	<a href="#">NCT04619628</a>				
53	PS	Protein subunit	CIGB-669 (RBD+AgHB)	3	Day 0 + 14 + 28 or Day 0 + 28 + 56	IN	Center for Genetic Engineering and Biotechnology (CIGB)	Phase 1/2			<a href="#">RPCEC00000345</a>		
54	PS	Protein subunit	CIGB-66 (RBD+aluminium hydroxide)	3	Day 0 + 14 + 28 or Day 0 + 28 + 56	IM	Center for Genetic Engineering and Biotechnology (CIGB)	Phase 1/2			<a href="#">RPCEC00000346</a>		
55	IV	Inactivated Virus	VLA2001	2	Day 0 + 21	IM	Valneva, National Institute for Health Research, United Kingdom	Phase 1/2			<a href="#">NCT04671017</a>		
56	PS	Protein subunit	BECoV2	2	Day 0 + 28	IM	Biological E. Limited	Phase 1/2			<a href="#">CTRI/2020/11/029032</a>		
57	VVr	Viral vector (Replicating)	AdCLD-CoV19 (adenovirus vector)	1	Day 0	IM	Cellid Co., Ltd.	Phase 1/2			<a href="#">NCT04666012</a>		
58	DNA	DNA based vaccine	GLS-5310	2	Day 0 + 56 or Day 0 + 84	ID	GeneOne Life Science, Inc.	Phase 1/2			<a href="#">NCT04673149</a>		
59	PS	Protein subunit	Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted	2	Day 0 + 21	IM	Nanogen Pharmaceutical Biotechnology	Phase 1/2			<a href="#">NCT04683484</a>		
60	PS	Protein subunit	Recombinant protein vaccine S-268019 (using Baculovirus expression vector system)	2	Day 0 + 21	IM	Shionogi	Phase 1/2			<a href="#">jRCT2051200092</a>		
61	VVnr	Viral vector (Non-replicating)	AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein	1-2	Day 0	IN	Altimmune, Inc.	Phase 1	<a href="#">NCT04679909</a>				
62	PS	Protein subunit	SARS-CoV-2-RBD-Fc fusion protein			SC or IM	University Medical Center Groningen + Akston Biosciences Inc.	Phase 1/2			<a href="#">NCT04681092</a>		
63	IV	Inactivated Virus	ERUCOV-VAC, inactivated virus	2	Day 0 + 21	IM	Erciyes University	Phase 1	<a href="#">NCT04691947</a>				
64	PS	Protein subunit	COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant	2	Day 0 + 28	IM	University of Saskatchewan	Phase 1/2			<a href="#">NCT04702178</a>		
65	PS	Protein subunit	GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide)	2	Day 0 + 28	IM	SK Bioscience Co., Ltd.	Phase 1/2			<a href="#">NCT04742738</a> <a href="#">NCT04750343</a>		
66	PS	Protein subunit	Razi Cov Pars, recombinant spike protein	3	Day 0 + 21 + 51	IM and IN	Razi Vaccine and Serum Research Institute	Phase 1	<a href="#">IRCT20201214049709N1</a>				
67	IV	Inactivated Virus	COVID-19 inactivated vaccine	2	Day 0 + 14	IM	Shifa Pharmed Industrial Co	Phase 1	<a href="#">IRCT20201202049567N1</a>				
68	PS	Protein subunit	MF59 adjuvanted SARS-CoV-2 Sclamp vaccine	2	Day 0 + 28	IM	The University of Queensland	Phase 1	<a href="#">NCT04495933</a> <a href="#">Study Report</a>				

69	DNA	DNA based vaccine	COVIGEN	2	Day 0 + 28	ID or IM	University of Sydney, Bionet Co., Ltd Technovallia	Phase 1	<a href="#">NCT04742842</a>	
70	DNA	DNA based vaccine	COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein			IM	Takis + Rottapharm Biotech	Phase 1/2		<a href="#">EudraCT:2020-003734-20</a>
71	VVnr	Viral vector (Non-replicating)	BBV154, Adenoviral vector COVID-19 vaccine	1	Day 0	IN	Bharat Biotech International Limited	Phase 1	<a href="#">NCT04751682</a>	
72	DNA	DNA based vaccine	COVID-eVax, A plasmid DNA vaccine targeted Spike protein production			IM	Takis and Rottapharm Biotech	Phase 1/2		<a href="#">EUCTR2020-003734-20-IT</a>
73	RNA	RNA based vaccine	PTX-COVID19-B, mRNA vaccine	2	Day 0 + 28	IM	Providence Therapeutics	Phase 1	<a href="#">NCT04765436</a>	
74	VVr	Viral vector (Replicating)	NDV-HXP-S, Newcastle disease virus (NDV) vector expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018	2	Day 0 + 28	IM	Mahidol University; The Government Pharmaceutical Organization (GPO); Icahn School of Medicine at Mount Sinai	Phase 1/2		<a href="#">NCT04764422</a>
75	RNA	RNA based vaccine	CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen		Day 0 + 28	IM	GlaxoSmithKline	Phase 1	<a href="#">NCT04758962</a>	
76	VLP	Virus like particle	VBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant.	2	Day 0 + 28	IM	VBI Vaccines Inc.	Phase 1/2		<a href="#">NCT04773665</a>
77	PS	Protein subunit	SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) + adjuvanted with alum.	2	Day 0 + 28	IM	SK Bioscience Co., Ltd.	Phase 1	<a href="#">NCT04760743</a>	
78	VVnr	Viral vector (Non-replicating)	Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes.	2-3	Day 0 + 14 + 28 or Day 0 + 28 + 56 or Day 0 + 112	IM	Gritstone Oncology	Phase 1	<a href="#">NCT04776317</a>	
79	RNA	RNA based vaccine	mRNA-1273.351. A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant.	3	Day 0 or Day 0 + 28 or Day 56	IM	Moderna + National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	<a href="#">NCT04785144</a>	
80	PS	Protein subunit	SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant.	2-3	Day 0 + 28 + 180	IM	Walter Reed Army Institute of Research (WRAIR)	Phase 1	<a href="#">NCT04784767</a>	
81	PS	Protein subunit	EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant.	2	Day 0 + 21	IM	EuBiologics Co.,Ltd	Phase 1/2		<a href="#">NCT04783311</a>

Final evaluation (Trial registries and public reports)

Phase 2	Phase 2/3	Phase 3	Phase 4	Number of virologically confirmed (PCR or NAAT positive) symptomatic cases of COVID-19	Efficacy compared to placebo for the prevention of SARS-CoV-2 infection	Efficacy against severe and non-severe COVID-19: hospital admissions	Efficacy for the prevention of COVID-19-related Emergency Department visits	Efficacy of vaccine against severe and non-severe COVID-19	Efficacy of vaccine against severe and non-severe COVID-19: number of deaths	Efficacy: seroconversion rates	Assess humoral immunogenicity: antibody quantification
<a href="#">NCT04754698**</a>		<a href="#">NCT04456595</a> <a href="#">Study Protocol</a> <a href="#">NCT04508075</a> <a href="#">NCT04582344</a> <a href="#">NCT04617483</a> <a href="#">NCT04651790</a>	<a href="#">NCT04756830</a> <a href="#">NCT04747821</a> <a href="#">NCT04775069</a>	X	X			X		X	X
				X	X			X	X	X	X
				X	X	X		X	X	X	X
				X	X	X		X	X	X	X
		<a href="#">ChiCTR2000034780</a> <a href="#">ChiCTR2000039000</a> <a href="#">NCT04510207*</a> <a href="#">NCT04612972</a>		X	X			X	X	X	X
				X	X			X	X	X	X
		<a href="#">NCT04560881</a>	<a href="#">ChiCTR2100041704</a> <a href="#">ChiCTR2100041705</a> <a href="#">ChiCTR2100041706</a>	X	X			X		X	X
<a href="#">NCT04686773</a>	<a href="#">NCT04400838</a> <a href="#">Study Report</a> <a href="#">ISRCTN69254139</a> <a href="#">Study Report</a> <a href="#">Study Report</a> <a href="#">Study Report</a> <a href="#">CTRI/2020/08/027170</a> <a href="#">ISRCTN69254139</a>	<a href="#">ISRCTN89951424</a> <a href="#">NCT04516746</a> <a href="#">NCT04540393</a> <a href="#">NCT04536051</a> EUCTR2020-005226-28-DE <a href="#">Study Report</a> <a href="#">Study Report</a>	<a href="#">NCT04760132</a> <a href="#">NCT04775069</a>	X	X		X	X	X	X	X
				X	X			X	X	X	X
				X	X		X	X	X	X	X
				X	X			X	X	X	X
<a href="#">ChiCTR2000031781</a> <a href="#">NCT04566770</a> <a href="#">NCT04341389</a> <a href="#">Study Report</a>		<a href="#">NCT04526990</a> <a href="#">NCT04540419</a>		X	X			X		X	X
				X	X	X		X	X	X	X
		<a href="#">NCT04530396</a> <a href="#">Study Report</a>		X		X				X	X
<a href="#">NCT04587219</a>	<a href="#">NCT04640233</a>	<a href="#">NCT04564716</a> <a href="#">NCT04642339</a> <a href="#">NCT04656613</a> <a href="#">NCT04741061</a>		X	X					X	X
				X	X					X	X
				X	X					X	X
				X	X					X	X
<a href="#">EUCTR2020-002584-63-DE</a> <a href="#">NCT04535453</a> <a href="#">NCT04765384</a>		<a href="#">NCT04505722</a> <a href="#">Study Report</a> <a href="#">NCT04614948</a>		X	X	X		X		X	X
				X	X			X		X	X
<a href="#">NCT04533399</a>		<a href="#">NCT04611802</a> <a href="#">EUCTR2020-004123-16-GB</a> <a href="#">NCT04583995</a>		X	X			X		X	X
				X	X			X		X	X
				X	X	X		X		X	X









Phase 3 endpoint

Safety and immunogenicity of  
a booster dose

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x





